Business
CareDx to Report Third Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and
About this update from Caredx, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nCareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 3, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.\n\nIndividuals interested in listening to the conference call may do so by dialing 1-800-289-0438 for domestic callers or 1-323-794-2423 for international callers. Please reference Conference ID: 2768596. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com.\n\nAbout CareDx – The Transplant Company\n\nCareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20221026005194/en/\n\nCareDx, Inc.\nInvestor Relations\nIan Cooney\n415-287-2300 x 3550\[email protected]\n\nSource: CareDx, Inc.","length":3308,"tagName":"div"}]